IL151014A0 - Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure - Google Patents

Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure

Info

Publication number
IL151014A0
IL151014A0 IL15101401A IL15101401A IL151014A0 IL 151014 A0 IL151014 A0 IL 151014A0 IL 15101401 A IL15101401 A IL 15101401A IL 15101401 A IL15101401 A IL 15101401A IL 151014 A0 IL151014 A0 IL 151014A0
Authority
IL
Israel
Prior art keywords
treatment
fatty acid
heart failure
congestive heart
acid oxidation
Prior art date
Application number
IL15101401A
Other languages
English (en)
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of IL151014A0 publication Critical patent/IL151014A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15101401A 2000-02-18 2001-02-15 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure IL151014A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18356000P 2000-02-18 2000-02-18
US21990800P 2000-07-21 2000-07-21
PCT/US2001/004887 WO2001060348A2 (fr) 2000-02-18 2001-02-15 Inhibiteurs partiels de l'oxydation d'acides gras pour le traitement de l'insuffisance cardiaque globale

Publications (1)

Publication Number Publication Date
IL151014A0 true IL151014A0 (en) 2003-02-12

Family

ID=26879274

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15101401A IL151014A0 (en) 2000-02-18 2001-02-15 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure

Country Status (17)

Country Link
US (2) US6528511B2 (fr)
EP (2) EP1259230A2 (fr)
JP (1) JP2004505886A (fr)
KR (1) KR20020075801A (fr)
CN (1) CN1227004C (fr)
AR (1) AR033510A1 (fr)
AU (1) AU778203B2 (fr)
BR (1) BR0108452A (fr)
CA (1) CA2398691A1 (fr)
HK (1) HK1048250A1 (fr)
IL (1) IL151014A0 (fr)
MX (1) MXPA02007639A (fr)
NO (1) NO20023879D0 (fr)
NZ (1) NZ520780A (fr)
TW (1) TWI235655B (fr)
WO (1) WO2001060348A2 (fr)
ZA (1) ZA200206451B (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1227004C (zh) * 2000-02-18 2005-11-16 Cv治疗公司 治疗充血性心力衰竭的部分脂肪酸氧化抑制剂
WO2003037323A2 (fr) * 2001-10-26 2003-05-08 MEDIGENE AG Gesellschaft für Molekularbiologische Kardiologie und Onkologie Inhibiteurs de l'oxydation des acides gras pour la prophylaxie et le traitement des maladies liees a un dysfonctionnement mitochondrial
CA2466432A1 (fr) * 2001-11-08 2003-05-15 Atrium Medical Corporation Dispositif intraluminal avec revetement contenant une substance therapeutique
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
AU2003248558B8 (en) * 2002-05-21 2009-07-09 Gilead Sciences, Inc. Method of treating diabetes
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
JP2006510670A (ja) * 2002-12-05 2006-03-30 シーブイ・セラピューティクス・インコーポレイテッド 置換ヘテロ環化合物
EP1723129A1 (fr) * 2003-12-18 2006-11-22 Cv Therapeutics, Inc. Composes piperazine et piperazine 1-akan-2-ol substitues
CA2564679C (fr) † 2004-03-22 2015-06-23 Osiris Therapeutics, Inc. Cellules souches mesenchymateuses et leurs utilisations
US9801913B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Barrier layer
US9801982B2 (en) * 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
US8124127B2 (en) * 2005-10-15 2012-02-28 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
US9012506B2 (en) * 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US8312836B2 (en) 2004-09-28 2012-11-20 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
US20060067977A1 (en) * 2004-09-28 2006-03-30 Atrium Medical Corporation Pre-dried drug delivery coating for use with a stent
US20090011116A1 (en) * 2004-09-28 2009-01-08 Atrium Medical Corporation Reducing template with coating receptacle containing a medical device to be coated
US8367099B2 (en) 2004-09-28 2013-02-05 Atrium Medical Corporation Perforated fatty acid films
WO2006036970A2 (fr) * 2004-09-28 2006-04-06 Atrium Medical Corporation Procede permettant d'epaissir un revetement a l'aide d'un medicament
US9000040B2 (en) * 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
JP2008519770A (ja) * 2004-11-09 2008-06-12 シーブイ・セラピューティクス・インコーポレイテッド 心不全の処置における左室リモデリングを逆転させるための少なくとも１種のリモデリング物質と併用するラノラジンの使用
JP2008533044A (ja) * 2005-03-11 2008-08-21 ホン コン ナイトリック オキサイド リミテッド 内皮機能不全、アンギナおよび糖尿病のための組合せ治療
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US7606617B2 (en) * 2006-01-31 2009-10-20 Cardiac Pacemakers, Inc. Urinalysis for the early detection of and recovery from worsening heart failure
EP2051748A2 (fr) * 2006-09-08 2009-04-29 Symphony Medical, INC. Modelage intramyocardique destiné à un redimensionnement et une reformation cardiaques complets
EP2083875B1 (fr) * 2006-11-06 2013-03-27 Atrium Medical Corporation Filet chirurgical enrobe
US9492596B2 (en) * 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
CA2678272A1 (fr) * 2007-02-13 2008-10-02 Cv Therapeutics, Inc. Utilisation de la ranolazine pour le traitement de maladies cardiovasculaires
CA2678319A1 (fr) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Utilisation de la ranolazine dans le traitement des maladies microvasculaires coronaires
EP2117550A1 (fr) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Utilisation de la ranolazine pour le traitement de maladies microvasculaires non coronariennes
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
CA2682160C (fr) * 2007-04-11 2017-04-04 Henry Ford Health System Reparation, redimensionnement et remise en forme du coeur a l'aide du systeme veineux du coeur
CA2689633A1 (fr) * 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Utilisation de ranolazine pour peptide cerebral natriuretique eleve
CN101066253B (zh) * 2007-06-07 2011-01-05 北京本草天源药物研究院 一种雷诺嗪缓释片
WO2008154033A2 (fr) * 2007-06-11 2008-12-18 Symphony Medical, Inc. Configuration cardiaque pour améliorer la fonction diastolique
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
BRPI0908428A2 (pt) * 2008-02-06 2015-12-08 Gilead Sciences Inc uso de ranozalina para tratar a dor.
WO2010132696A1 (fr) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine pour le traitement de troubles du snc
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
WO2011036677A2 (fr) * 2009-09-25 2011-03-31 Lupin Limited Composition de ranolazine à libération prolongée
WO2012009707A2 (fr) 2010-07-16 2012-01-19 Atrium Medical Corporation Composition et procédés destinés à modifier la vitesse d'hydrolyse de substances vulcanisées à base d'huile
EP2524688B1 (fr) * 2011-05-11 2013-05-01 ratiopharm GmbH Composition de libération modifiée comportant de la ranolazine
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
CN104758265B (zh) * 2014-01-07 2019-05-17 四川海思科制药有限公司 一种雷诺嗪缓释片药物组合物及其制备方法
FR3060567B1 (fr) 2016-12-19 2019-05-24 Ecole Normale Superieure De Lyon Substrat de glycosidase fluorogene et procede de detection associe
CN112438955A (zh) * 2019-08-30 2021-03-05 深圳翰宇药业股份有限公司 一种雷诺嗪缓释组合物及其制备方法
GR1010510B (el) * 2022-06-07 2023-07-20 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5001193A (en) 1988-12-22 1991-03-19 American Cyanamid Epoxy adhesive for bonding of automotive parts made from bulk or sheet molding compound containing polymeric toughening agent and Mannich Base
DE69034000T2 (de) 1989-06-23 2003-06-05 Syntex (U.S.A.) Llc, Palo Alto Ranolazin und verwandte Piperazine zum Schutz der Skelettmuskulatur
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
US6083532A (en) 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
CN1227004C (zh) * 2000-02-18 2005-11-16 Cv治疗公司 治疗充血性心力衰竭的部分脂肪酸氧化抑制剂
MXPA02008213A (es) * 2000-02-22 2004-04-05 Cv Therapeutics Inc Compuestos piperazina sustituidos.

Also Published As

Publication number Publication date
EP2033633A3 (fr) 2009-07-08
HK1048250A1 (zh) 2003-03-28
ZA200206451B (en) 2003-12-31
NO20023879L (no) 2002-08-15
AU778203B2 (en) 2004-11-25
AR033510A1 (es) 2003-12-26
WO2001060348A2 (fr) 2001-08-23
AU4150501A (en) 2001-08-27
US20010047000A1 (en) 2001-11-29
KR20020075801A (ko) 2002-10-05
NZ520780A (en) 2006-04-28
BR0108452A (pt) 2003-04-01
JP2004505886A (ja) 2004-02-26
CA2398691A1 (fr) 2001-08-23
WO2001060348A3 (fr) 2002-01-31
US20030119718A1 (en) 2003-06-26
EP1259230A2 (fr) 2002-11-27
EP2033633A2 (fr) 2009-03-11
TWI235655B (en) 2005-07-11
CN1420766A (zh) 2003-05-28
CN1227004C (zh) 2005-11-16
US6677342B2 (en) 2004-01-13
NO20023879D0 (no) 2002-08-15
MXPA02007639A (es) 2004-08-23
US6528511B2 (en) 2003-03-04

Similar Documents

Publication Publication Date Title
IL151014A0 (en) Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
HK1073441A1 (en) Administration of a partial fatty acid oxidation inhibitor such as ranolazine for the treatment of diabetes
HK1069815A1 (en) Omega-aminoalkylamides of r-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells
AU8707601A (en) Heart support to prevent ventricular remodeling
IL159816A0 (en) In-vivo method and device for improving diastolic function of the left ventricle
AU2001249881A1 (en) Method of treating the heart
IL160065A0 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
ZA200107122B (en) Treatment of acne using lipoic acid.
HK1085615A1 (en) Fatty acid desaturases from fungi
HK1048443B (zh) 用於治療外分泌失調的脂肪酸衍生物
NO20031784D0 (no) Heteroarylalkylpiperazinderivater som fettsyre- oksydasjonsinhibitorer
IL149251A0 (en) Diagnosis and treatment of cardiovascular conditions
IL154802A0 (en) New oxabispidine compound useful in the treatment of cardiac arrhythmias
HUP0301059A3 (en) Use of lactic acid bacterium for the treatment of peritonitis
EP1340740A4 (fr) Lipide de type acide carboxylique
GB0111594D0 (en) Pipecolnic acid derivatives method of manufacturing the same and therapeutic agents containing these compounds
GB0006866D0 (en) Low Ph high fatty acid vanishing cream
GB0006865D0 (en) Low pH high fatty acid vanishing cream
AU8609201A (en) Reduction of the electrocardiographic ot interval
GB9907082D0 (en) The preparation of carboxylic acid derivatives
PL338405A1 (en) Method of obtaining 2-quinoxalincarboxylic acid
AU2001289723A1 (en) Novel use of difluoromalonic acid esters
HU0000015V0 (en) Junction arrangement for treatment of acid accumulators
GB0018320D0 (en) Method of safely oxidizing fat molecules in vivo
EE04960B1 (et) Meetod arliminometlkarbamiinhappeestrite valmistamiseks